Platform ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	3

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04387734 (ClinicalTrials.gov)	February 5, 2021	11/5/2020	Effects of Ocrevus in Relapsing Multiple Sclerosis	Effects and Mechanisms of Ocrevus on Ambulatory Functions in People With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: Ocrelizumab;Drug: Platform	Georgia State University	Multiple Sclerosis Center of Atlanta	Recruiting	18 Years	65 Years	All	60	Phase 4	United States
2	NCT03353974 (ClinicalTrials.gov)	December 1, 2017	16/11/2017	Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients.	The Role of Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients. A Pilot Randomized Controlled Trial.	Multiple Sclerosis	Device: Video game therapy;Device: Balance platform therapy	University Hospital of Ferrara	NULL	Recruiting	18 Years	60 Years	All	48	N/A	Italy
3	NCT04289675 (ClinicalTrials.gov)	January 1, 2012	27/12/2019	Multiple Sclerosis: Chi3L1 and Treatment Efficacy	Chi3L1: A Marker of Efficacy of Platform Treatments in Relapsing-onset Multiple Sclerosis: A Prognostic Study on Existing Clinical Data and Biological Samples	Multiple Sclerosis	Drug: Interferon-Beta	Central Hospital, Nancy, France	NULL	Completed	18 Years	55 Years	All	63		NULL